By Neuroscience News
June 7, 2012
CAD106, a new vaccine for Alzheimer's disease has successfully finished the first trial and is ready for go to the final trial with a larger amount of subjects. In this trial, the vaccine was modified to only affect the harmful beta-amyloid (what is believed to be the root to Alzheimer's disease). In the trial is was found that 80% of the patients were able to develop their own protective antibodies against beta-amyloid without side-effects. The researchers believe CAD106 is an appropriate treatment for patients who have mild to moderate Alzheimer's. Next step is to conduct larger trials to be positive of these results.
No comments:
Post a Comment